🟢 Cardio Diagnostics Holdings is trading 6.77% up in pre-market after August 20 call on commercialization roadmap

Cardio Diagnostics Holdings is trading 6.77% up at $2.36 after its August 20, 2026 investor presentation and call focused on its commercialization roadmap, AI-driven cardiovascular tests, reimbursement progress, and strategic growth initiatives.

• The move follows an 11.06% gain to $2.21 on August 20.
• The call covered Epi+Gen CHD, PrecisionCHD, ongoing studies, and Medicare pricing.
• Broader pre-market indices were also modestly higher.